Loyal's application for the lifespan extension drug LOY-002 is progressing towards potential approval by the FDA Center for Veterinary Medicine. The company announced that the target animal safety (TAS) technical section of its conditional approval application has been accepted by the agency. This marks acceptance of two of the three major technical sections needed for market launch.
Read More
The FDA had previously granted a reasonable expectation of effectiveness designation for LOY-002, which is a prescription pill aimed at improving quality of life in dogs aged 10 and older that weigh at least 14 pounds. The final technical section, concerning manufacturing, must be accepted for conditional approval to proceed.
Dr. Ellen Ratcliff, vice president of clinical and veterinary medicine at Loyal, emphasized the importance of safety in preventive care, calling the FDA's sign-off an important endorsement of the company’s mission to create safe and effective lifespan extension drugs for dogs.
Loyal anticipates that the review of the final major technical section will occur in 2027. Dr. Brennen McKenzie, director of veterinary medicine for Loyal, stated that work on the mechanical section of the application is ongoing. Full approval for LOY-002 would follow the completion of the STAY study, which is the main effectiveness trial necessary for a future full new animal drug application.
The development focuses on addressing age-related metabolic dysfunction, which is seen as a significant risk factor for health issues in senior dogs. McKenzie believes that improving metabolic health can extend both lifespan and health span, allowing dogs to enjoy their activities longer.
The safety data submitted to the FDA includes results from various scientific investigations, highlighting no clinically significant adverse events at standard dose strengths. This includes data from the STAY study, which, as of July 2025, enrolled 1,300 dogs across 70 veterinary clinics in the U.S. The FDA has determined that the safety data supports LOY-002’s intended use.
If approved, LOY-002 would be the first drug approved by the FDA for lifespan extension in any species, according to Loyal. Celine Halioua, founder and CEO of Loyal, expressed that achieving this safety acceptance brings them closer to realizing their goal of introducing the first longevity drug for dogs to the market.